These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38966764)

  • 1. Durable response to nivolumab rechallenge in a patient with metastatic clear cell renal cell carcinoma.
    Fujiwara M; Shimada W; Yokoyama M; Koyanagi A; Shintaku H; Fukuda S; Waseda Y; Tanaka H; Yoshida S; Fujii Y
    IJU Case Rep; 2024 Jul; 7(4):293-296. PubMed ID: 38966764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of rechallenge nivolumab in a hemodialysis patient with multiple metastases from a rapidly progressed T1a renal clear cell carcinoma: An autopsy case.
    Hanawa K; Sawada N; Yokota Y; Aikawa J; Otake Y; Sugimura K; Shimura H; Mochizuki T; Kira S; Mitsui T
    IJU Case Rep; 2024 May; 7(3):202-205. PubMed ID: 38686062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
    Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
    Front Immunol; 2022; 13():984132. PubMed ID: 36189265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma.
    Billon E; Walz J; Brunelle S; Thomassin J; Salem N; Guerin M; Vicier C; Dermeche S; Albiges L; Tantot F; Nenan S; Pignot G; Gravis G
    Front Oncol; 2019; 9():1033. PubMed ID: 31649889
    [No Abstract]   [Full Text] [Related]  

  • 5. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
    Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
    J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Only three cycles of nivolumab showed remarkable durable response and reversible myeloradiculoneuropathy in a patient with metastatic papillary renal cell carcinoma type 2.
    Iwasaki K; Shin T; Inoue T; Shibuya T; Hirai K; Ando T; Mimata H
    IJU Case Rep; 2021 May; 4(3):139-142. PubMed ID: 33977240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma.
    George G; Schmidt L; Tolat P; Riese M; Kilari D
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report.
    Murata M; Ikeda Y; Hasegawa G; Nakagawa Y; Nishiyama T
    J Med Case Rep; 2019 Apr; 13(1):98. PubMed ID: 31006385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitiligo-like Depigmentation in a Patient Undergoing Treatment with Nivolumab for Advanced Renal-cell Carcinoma.
    Navarro-Fernandez I; Gonzalez-Vela C; Gomez-Fernandez C; Duran-Vian C; Reguero L; Gonzalez-Lopez M
    Acta Dermatovenerol Croat; 2021 Apr; 291(1):54-55. PubMed ID: 34477066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy.
    Yoshida K; Takagi T; Kondo T; Kobayashi H; Iizuka J; Fukuda H; Ishihara H; Okumi M; Ishida H; Tanabe K
    Jpn J Clin Oncol; 2019 Jun; 49(6):576-580. PubMed ID: 30924496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab.
    Tomioka M; Nakane K; Ozawa K; Iinuma K; Suzui N; Miyazaki T; Koie T
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1356. PubMed ID: 33656804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Successful Re-Administration of Nivolumab in Patient with Metastatic Renal Cell Carcinoma : A Case Report].
    Sasagawa H; Numakura K; Nakamura G; Kukimoto T; Kikuchi A; Sagehashi R; Yamamoto R; Koizumi A; Nara T; Kanda S; Saito M; Narita S; Inoue T; Satoh S; Habuchi T
    Hinyokika Kiyo; 2021 Dec; 67(12):525-528. PubMed ID: 34991292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma.
    Nakajima N; Kano T; Oda K; Uchida T; Otaki T; Nagao K; Shimizu Y; Kawakami M; Kim H; Nitta M; Hasegawa M; Kawamura Y; Miyajima A
    IJU Case Rep; 2020 Sep; 3(5):215-218. PubMed ID: 32914080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-Challenging with Nivolumab in Metastatic Renal Cell Carcinoma After Immune-Related Interstitial Pneumonia: A Case Report.
    Shibata Y; Noguchi G; Suzuki T; Osaka K; Umemoto S; Kishida T
    Am J Case Rep; 2021 Aug; 22():e932924. PubMed ID: 34358221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durable response after interruption of nivolumab in patients with metastatic renal cell carcinoma: Is renal toxicity a marker to predict the benefit of nivolumab?
    Kus T; Aktas G
    J Oncol Pharm Pract; 2020 Jun; 26(4):1000-1004. PubMed ID: 31594517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A CASE OF UNRESECTABLE METASTATIC RENAL CARCINOMA SUCCESSFULLY TREATED BY COMBINED MODALITY THERAPY WITH NIVOLUMAB AND SURGERY].
    Ohmori N; Oki T; Tahara H
    Nihon Hinyokika Gakkai Zasshi; 2021; 112(2):105-108. PubMed ID: 35444078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safe administration of ipilimumab plus nivolumab to a dialysis patient with renal cell carcinoma.
    Iwaki T; Niimi A; Kano M; Kurokawa Y; Yoshizaki U; Nozaki K; Nomiya A; Miyazaki H; Kume H
    IJU Case Rep; 2021 Jan; 4(1):32-35. PubMed ID: 33426493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
    In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.